Lexeo Therapeutics, Valuation
| LXEO Stock | 4.43 0.34 8.31% |
At this time, the firm appears to be undervalued. Lexeo Therapeutics, secures a last-minute Real Value of USD8.4 per share. The latest price of the firm is USD4.43. Our model forecasts the value of Lexeo Therapeutics, from analyzing the firm fundamentals such as Return On Equity of -1.07, shares owned by insiders of 1.25 %, and Current Valuation of 23.69 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lexeo Therapeutics,'s valuation include:
Undervalued
Today
Please note that Lexeo Therapeutics,'s price fluctuation is unstable at this time. Calculation of the real value of Lexeo Therapeutics, is based on 3 months time horizon. Increasing Lexeo Therapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lexeo Therapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lexeo Stock. However, Lexeo Therapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.43 | Real 8.4 | Target 22.43 | Hype 3.75 | Naive 4.49 |
The intrinsic value of Lexeo Therapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lexeo Therapeutics,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lexeo Therapeutics, Common helps investors to forecast how Lexeo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lexeo Therapeutics, more accurately as focusing exclusively on Lexeo Therapeutics,'s fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lexeo Therapeutics,'s intrinsic value based on its ongoing forecasts of Lexeo Therapeutics,'s financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lexeo Therapeutics,'s closest peers.
Lexeo Therapeutics, Cash |
|
Lexeo Valuation Trend
Knowing Lexeo Therapeutics,'s actual value is paramount for traders when making sound investment determinations. Using both Lexeo Therapeutics,'s enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Lexeo Therapeutics, Total Value Analysis
Lexeo Therapeutics, Common is now forecasted to have valuation of 23.69 M with market capitalization of 135.29 M, debt of 11.64 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lexeo Therapeutics, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
23.69 M | 135.29 M | 11.64 M |
Lexeo Therapeutics, Asset Utilization
One of the ways to look at asset utilization of Lexeo is to check how much profit was generated for every dollar of assets it reports. Lexeo Therapeutics, Common secures a negative usage of assets of -0.51 %, losing USD0.005105 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Lexeo Therapeutics, Common shows how discouraging it operates for each dollar spent on its assets.Lexeo Therapeutics, Ownership Allocation
The majority of Lexeo Therapeutics, outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Lexeo Therapeutics, Common to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Lexeo Therapeutics,. Please pay attention to any change in the institutional holdings of Lexeo Therapeutics, as this could imply that something significant has changed or is about to change at the company.Lexeo Therapeutics, Profitability Analysis
Net Loss for the year was (66.39 M) with loss before overhead, payroll, taxes, and interest of (63.94 M).About Lexeo Therapeutics, Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Lexeo Therapeutics, Common. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Lexeo Therapeutics, based exclusively on its fundamental and basic technical indicators. By analyzing Lexeo Therapeutics,'s financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Lexeo Therapeutics,'s intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lexeo Therapeutics,. We calculate exposure to Lexeo Therapeutics,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lexeo Therapeutics,'s related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.7 M | -1.6 M | |
| Pretax Profit Margin | (104.23) | (99.02) | |
| Operating Profit Margin | (106.40) | (101.08) | |
| Net Loss | (104.23) | (99.02) | |
| Gross Profit Margin | (0.86) | (0.82) |
Lexeo Therapeutics, Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 26.6 M |
Lexeo Therapeutics, Current Valuation Indicators
Lexeo Therapeutics,'s valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Lexeo Therapeutics,'s valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lexeo Therapeutics,, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lexeo Therapeutics,'s valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lexeo Therapeutics,'s worth.When determining whether Lexeo Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexeo Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexeo Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexeo Therapeutics, Common Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexeo Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.